Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;6(7):523-524.
doi: 10.1016/S2468-1253(21)00194-1.

SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply

James L Alexander  1 , Nicholas A Kennedy  2 , Charlie W Lees  3 , Tariq Ahmad  2 , Nick Powell  4 ; British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group
Affiliations
Comment

SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply

James L Alexander et al. Lancet Gastroenterol Hepatol. 2021 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JLA reports sponsorship from Vifor Pharma for accommodation and travel to British Society of Gastroenterology 2019. NAK reports personal fees from Dr Falk, Janssen, Takeda, and Tillotts; and grants and personal fees from Pharmacosmos. TA reports grants from F Hoffmann-La Roche AG, Janssen, and Galapagos; grants and personal fees from Biogen, Celltrion, and Celgene; non-financial support from AbbVie and Tillotts; personal fees from Arena, Adcock Ingram, Gilead, Pfizer, and Genentech; and grants, personal fees, and non-financial support from Takeda. CWL reports grants and personal fees from Gilead; and personal fees from AbbVie, Takeda, Janssen, Ferring, Trellus Health, Pfizer, Galapagos, and Iterative Scopes. NP reports serving as a speaker for Allergan, Bristol Myers Squibb, Falk, Ferring, Janssen, Pfizer, Tillotts, and Takeda, and as a consultant and/or an advisory board member for AbbVie, Allergan, Celgene, Bristol Myers Squibb, Ferring, and Vifor Pharma.

Comment on

References

    1. Alexander JL, Moran GW, Gaya DR, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6:218–224. - PMC - PubMed
    1. van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis. Vaccine. 2018;36:5832–5845. - PubMed
    1. van Aalst M, Garcia Garrido HM, van der Leun J, et al. Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease. Clin Infect Dis. 2020;70:595–604. - PubMed
    1. Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021 doi: 10.1136/gutjnl-2021-324789. published online April 26. - DOI - PubMed
    1. Wong SY, Dixon R, Pazos VM, et al. Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies. Gastroenterology. 2021 doi: 10.1053/j.gastro.2021.04.025. published online April 19. - DOI

Substances